Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: A subanalysis of the Treating to New Targets (TNT) study.

CONCLUSIONS: Treatment with high-dose atorvastatin to a mean LDL-C level of 2.0 mmol/l (77 mg/dl) considerably attenuated the predictive power associated with three MetS components. PMID: 26434404 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26434404?dopt=Abstract

Source: Diabetes Metab - October 5, 2015 Category: Endocrinology Authors: Deedwania PC, Shepherd J, Breazna A, DeMicco DA Tags: Diabetes Obes Metab Source Type: research